SPOTLIGHT -
Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.
Outlook Therapeutics submits UK Marketing Authorization Application for wet AMD treatment
I-SCREEN project set to use AI for AMD diagnosis across Europe
India-based Eyestem receives approval to commence human trial for Eyecyte RPE for AMD
EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901
John Han, PharmD named Vice President, Medical Affairs for Opthea Limited
Clinical trials: Companies tackle AMD in early 2024